A very recent study demonstrates that in a mouse model of AD the treatment with FPR antagonist, Boc2, significantly improved spatial memory performance, decreased neuronal damage, caused the expression of homeostatic growth factors and ameliorated microglia, but not astrocyte, reactivity. The gene discussed is FPR1; the disease is Alzheimer disease.